Advertisement

Pharmaceutisch Weekblad

, Volume 9, Issue 3, pp 162–171 | Cite as

Liposomes in treatment of infectious diseases

  • F. Emmen
  • G. Storm
Review Articles

Abstract

In reviewing the literature about the potential of liposomes in the therapy of infections caused by protozoa, bacteria, fungi and viruses, it can be concluded that liposomal encapsulation may improve the therapeutic index of anti-infectious drugs. The improved therapeutic index may be a result of a reduction in drug toxicity and/or an enhanced drug delivery at the intracellular site of infection. Furthermore, attention is paid to the therapeutic utility of liposome-encapsulated immunomodulators in treatment of infections.

Key words

Administration, parenteral Antibiotics Antifungal agents Antiprotozoal agents Drug targeting Immunologic factors Liposomes Macrophages 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Richardson VJ. Liposomes in antimicrobial chemotherapy. J Antimicrob Chemother 1983;12:532–4.PubMedGoogle Scholar
  2. 2.
    Alving CR. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther 1983;22:407–24.PubMedGoogle Scholar
  3. 3.
    Schroit AJ, Hart IR, Madsen J, Fidler IJ. Selective delivery of drugs encapsulated in liposomes: natural targeting to macrophages involved in various disease states. J Biol Response Mod 1983;2:97–100.PubMedGoogle Scholar
  4. 4.
    Baillie AJ. Intracellular infection and drug targeting. Pharm Int 1984;5:168–72.Google Scholar
  5. 5.
    Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev 1984;36:277–336.PubMedGoogle Scholar
  6. 6.
    Koff WC, Fidler IJ. The potential use of liposome-mediated antiviral therapy. Antiviral Res 1985;5:179–90.PubMedGoogle Scholar
  7. 7.
    Bakker-Woudenberg IAJM, Roerdink FH. Antimicrobial chemotherapy directed by liposomes. J Antimicrob Chemother 1986;17:547–52.PubMedGoogle Scholar
  8. 8.
    Croft SL. Liposomes in treatment of parasitic diseases. Pharm Int 1986;7:229–33.Google Scholar
  9. 9.
    Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238–52.PubMedGoogle Scholar
  10. 10.
    Crommelin DJA. Liposomen: karakterisering en stabiliteit [Liposomes: characterization and stability]. Pharm Weekbl 1982;117:1154–9.Google Scholar
  11. 11.
    Kirby C, Clark J, Gregoriadis G. Effect of cholesterol content of small unilamellar liposomes on their stabilityin vivo andin vitro. Biochem J 1980;186:591–8.PubMedGoogle Scholar
  12. 12.
    Kimelberg HK, Mayhew EG. Properties and biological effects of liposomes and their uses in pharmacology and toxicity. CRC Crit Rev Toxicol 1978;6:25–79.Google Scholar
  13. 13.
    Roerdink F, Dijkstra J, Hartman G, Bolscher B, Scherphof G. The involvement of parenchymal, Kupffer and endothelial liver cells in hepatic uptake of intravenously injected liposomes. Biochim Biophys Acta 1981;677:79–89.PubMedGoogle Scholar
  14. 14.
    Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ. Analysis of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1982;42:1412–22.PubMedGoogle Scholar
  15. 15.
    Dijkstra J, Van Galen M, Scherphof GL. Effects of ammonium chloride and chloroquine on endocytic uptake of liposomes by Kupffer cellsin vitro. Biochim Biophys Acta 1984;804:58–67.PubMedGoogle Scholar
  16. 16.
    Dijkstra J, Van Galen M, Regts J, Scherphof GL. Uptake and processing of liposomal phospholipids by Kupffer cellsin vitro. Eur J Biochem 1985;148:391–97.PubMedGoogle Scholar
  17. 17.
    Juliano RL, Stamp D. The effect of particle size and charge on the clearance rate of liposomes and liposome-encapsulated drugs. Biochem Biophys Res Commun 1975;63:651–8.PubMedGoogle Scholar
  18. 18.
    Poste G. Liposome targetingin vivo: problems and opportunities. Biol Cell 1983;47:19–37.Google Scholar
  19. 19.
    Rosenstreich DL. Cellular Functions in Immunity and Inflammation. New York: Elsevier/North Holland, 1981:127–59.Google Scholar
  20. 20.
    Blanden RV. T-cell response to viral and bacterial infections. Transplant Rev 1974;19:46–88.Google Scholar
  21. 21.
    Fidler IJ, Poste G. Macrophage-mediated destraction of malignant tumor cells and new strategies for the therapy of metastatic diseases. Springer Semin Immunopathol 1982;4:161–74.Google Scholar
  22. 22.
    Juliano RL, Stamp D. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Biochem Pharmacol 1978;27:21–7.PubMedGoogle Scholar
  23. 23.
    Marsden PD. Current concepts in parasitology: leishmaniasis. N Engl J Med 1980;303:145–55.PubMedGoogle Scholar
  24. 24.
    Weldon JS, Munnell JF, Hanson WL, Alving CR. Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of intracellular pathway. Z Parasitol 1983;69:415–24.Google Scholar
  25. 25.
    Heath S, Chance ML, New RRC. Quantitative and ultrastructural studies on the uptake of drug loaded liposomes by mononuclear phagocytes infected withLeishmania donovani. Mol Biochem Parasitol 1984;12:49–60.PubMedGoogle Scholar
  26. 26.
    New RRC, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981;8:371–81.PubMedGoogle Scholar
  27. 27.
    Hwang KJ, Mauk MR. Fate of lipid vesiclesin vivo: a gamma-ray perturbed angular correlation study. Proc Natl Acad Sci USA 1977;74:4991–5.PubMedGoogle Scholar
  28. 28.
    New RRC, Chance ML, Heath S. The treatment of experimental cutaneous leishmaniasis with liposome-entrapped pentostam. Parasitology 1981;83:519–27.Google Scholar
  29. 29.
    Verhave JP, Meuwissen JHETh, Golenser J. The dual role of macrophages in sporozoite induced malaria infection — a hypothesis. Int J Nucl Med Biol 1980;7:149–56.PubMedGoogle Scholar
  30. 30.
    Smith JE, Sinden RE. Studies on the uptake of sporozoites ofP. yoelii nigeriensis by perfused rat liver. Trans R Soc Trop Med Hyg 1981;75:188–9.Google Scholar
  31. 31.
    Sinden RE, Smith JE. The role of the Kupffer cell in the infection of rodents by sporozoites ofPlasmodium: uptake of sporozoites by perfused liver and the establishment of infectionin vivo. Acta Trop 1982;39:11–27.PubMedGoogle Scholar
  32. 32.
    Thompson PE, Werbel LM. Antimalarial Agents. New York: Academic Press, 1972.Google Scholar
  33. 33.
    Tarlov AR, Drewer GJ, Carson PE, Alving AS. Primaquine sensitivity. Arch Intern Med 1962;109:209–34.PubMedGoogle Scholar
  34. 34.
    Pirson P, Steiger RF, Trouet A, Gillet J, Herman F. Primaquine liposomes in the chemotherapy of experimental murine malaria. Ann Trop Med Parasitol 1980;74:383–91.PubMedGoogle Scholar
  35. 35.
    Pirson P, Steiger R, Sinden RE. The disposition of free and liposomally encapsulated antimalarial primaquine in mice. Biochem Pharmacol 1982;31:3501–7.PubMedGoogle Scholar
  36. 36.
    Suter E. Interactions between phagocytes and pathogenic organisms. Bacteriol Rev 1956;20:94–132.PubMedGoogle Scholar
  37. 37.
    Collins FM. Mechanisms of acquired resistance toPasteurella multocida infection: a review. Cornell Vet 1977;76:103–38.Google Scholar
  38. 38.
    Collins FM, Campbell SG. Immunity to intracellular bacteria. Vet Immunol Immunopathol 1982;3:5–66.PubMedGoogle Scholar
  39. 39.
    Bakker-Woudenberg IAJM, Roerdink FH, Scherphof G. Liposomes as drug Carriers: Trends and Progress. Chichester: John Wiley & Sons Ltd. (in press).Google Scholar
  40. 40.
    Desiderio JV, Campbell SG. Intraphagocytic killing ofSalmonella typhimurium by liposome-encapsulated cephalotin. J Infect Dis 1983;148:563–70.PubMedGoogle Scholar
  41. 41.
    Ukena TE, Berlin RD. Effect of colchicine and vinblastine on the topographical separation of membrane functions. J Exp Med 1972;136:1–7.PubMedGoogle Scholar
  42. 42.
    Stevenson M, Baillie AJ, Richards RME. Enhanced activity of streptomycin and chloramphenicol against intracellularEscherichia coli in the J774 macrophage cell line mediated by liposome delivery. Antimicrob Agents Chemother 1983;24:742–9.PubMedGoogle Scholar
  43. 43.
    Bakker-Woudenberg IAJM, Lokerse AF, Vink-van den Berg JC, Roerdink FH, Michel MF. Effect of liposome-entrapped ampicillin on survival ofListeria monocytogenes in murine peritoneal macrophages. Antimicrob Agents Chemother 1986;30:295–300.PubMedGoogle Scholar
  44. 44.
    Stevenson M, Baillie AJ, Richards RME. Antibacterial activity of liposome entrapped chloramphenicol. J Pharm Pharmacol 1981;33(suppl):31.Google Scholar
  45. 45.
    Fountain MW, Weiss SJ, Fountain AG, Shen A, Lenk RP. Treatment ofBrucella canis andBrucella abortus in vitro andin vivo by stable plurilammelar vesicle-encapsulated aminoglycosides. J Infect Dis 1985;152:529–35.PubMedGoogle Scholar
  46. 46.
    Dees C, Fountain MW, Taylor JR, Schultz RD. Enhanced intraphagocytic killing ofBrucella abortus in bovine mononuclear cells by liposomes containing gentamicin. Vet Immunol Immunopathol 1985;8:171–82.PubMedGoogle Scholar
  47. 47.
    Bakker-Woudenberg IAJM, Lokerse AF, Roerdink FH, Regts D, Michel MF. Free versus liposome-entrapped ampicillin in treatment of infection due toListeria monocytogenes in normal and athymic (nude) mice. J Infect Dis 1985;151:917–24.PubMedGoogle Scholar
  48. 48.
    Inagaki J, Rodriquez V, Bodey GP. Causes of death in cancer patients. Cancer 1974;33:568–74.PubMedGoogle Scholar
  49. 49.
    Edwards JE, Lehrer RI, Stiehm ER, Fischer TJ, Young LS. Severecandidal infections: clinical perspective, immune defense mechanism and current concepts of therapy. Ann Intern Med 1978;89:91–106.PubMedGoogle Scholar
  50. 50.
    Miller RP, Bates JH. Amphotericin B toxicity. Ann Intern Med 1969;71:1089–96.PubMedGoogle Scholar
  51. 51.
    Lopez-Berestein G, Mehta R, Hopfer RL, et al. Treatment and prophylaxis of disseminated infection due toCandida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983;147:939–45.PubMedGoogle Scholar
  52. 52.
    Juliano R, Lopez-Berestein G, Mehta R, Hopfer R, Mehta K, Lasi L. Pharmacokinetic and therapeutic consequences of liposomal drug delivery: fluorodeoxyuridine and amphotericin B. Biol Cell 1983;47:39–46.Google Scholar
  53. 53.
    Tremblay C, Barza M, Fiore C, Szoka F. Efficacy of liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 1984;26:170–3.PubMedGoogle Scholar
  54. 54.
    Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982;145:748–52.PubMedGoogle Scholar
  55. 55.
    Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis 1982;145:748–52.Google Scholar
  56. 56.
    Lopez-Berestein G, Rosenblum MG, Mehta RT. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected withCandida albicans. Cancer Drug Del 1984;1:199–205.Google Scholar
  57. 57.
    Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985;4:704–10.Google Scholar
  58. 58.
    Shirkoda A, Lopez-Berestein G, Holbert JM, Luna MA. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal AMB. Radiology 1986;159:349–53.PubMedGoogle Scholar
  59. 59.
    Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984;770:230–4.PubMedGoogle Scholar
  60. 60.
    Hopfer RL, Mills K, Mehta RT, Lopez-Berestein G, Faistein V, Juliano RL.In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother 1984;25:387–9.PubMedGoogle Scholar
  61. 61.
    Lopez-Berestein G, Hopfer RL, Mehta RT, Mehta K, Hersh EM, Juliano RL. Liposome-encapsulated amphotericin B for treatment of disseminatedcandidiasis in neutropenic mice. J Infect Dis 1984;150:278–83.PubMedGoogle Scholar
  62. 62.
    Mehta RT, Mehta K, Lopez-Berestein G, Juliano RL. Effect of liposomal amphotericin B on murine macrophages and lymphocytes. Infect Immun 1985;47:429–33.PubMedGoogle Scholar
  63. 63.
    Fidler IJ. Macrophages and metastases — a biological approach to cancer therapy. Cancer Res 1985;45:4714–26.PubMedGoogle Scholar
  64. 64.
    Allison AC. On the role of mononuclear phagocytes in immunity against viruses. Prog Med Virol 1974;18:15–31.PubMedGoogle Scholar
  65. 65.
    Chedid L, Carelli DA, Ardibert F. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothelial Soc 1979;26:631–40.Google Scholar
  66. 66.
    Koff WC, Showalter SD, Hampar B, Fidler IJ. Protection of mice against fatal Herpes simplex type 2 infection by liposomes containing muramyldipeptide. Science 1985;228:495–7.PubMedGoogle Scholar
  67. 67.
    Kende N, Schroit AJ, Rill W, Canonico P. Treatment of Rift Valley fever virus infected Swiss mice with liposome encapsulated muramyldipeptide [Abstract]. Las Vegas. Washington: International Congress of Antimicrobial Agents in Chemotherapy, 1983:108.Google Scholar
  68. 68.
    Fraser-Smith EB, Eppstein DA, Larsen MA, Matthews TR. Protective effect of muramyl dipeptide analog encapsulated in or mixed with liposomes againstCandida albicans infection. Infect Immun 1983;39:172.PubMedGoogle Scholar
  69. 69.
    Johnson RT. Viral Infections of the Nervous System. New York: Raven Press, 1982.Google Scholar
  70. 70.
    Shillitoe EJ, Rapp G. Virus-induced cell surface antigens and cell-mediated immune responses. Springer Semin Immunopathol 1979;2:237–59.Google Scholar
  71. 71.
    Koff WC, Showalter SD, Seniff DA, Hampar B. Lysis of Herpesvirus-infected cells by macrophages activated with free or liposome-encapsulated lymphokine produced by a murine T cell hybridoma. Infect Immun 1983;42:1067–72.PubMedGoogle Scholar
  72. 72.
    Koff WC, Fidler IJ, Showalter SD, et al. Human monocytes activated by immunomodulators in liposomes lyse Herpesvirus-infected but not normal cells. Science 1984;224:1007–9.PubMedGoogle Scholar
  73. 73.
    Fidler IJ, Sone S, Fogler WE, Barnes Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyldipeptide. Proc Natl Acad Sci USA 1981;78:1680.PubMedGoogle Scholar
  74. 74.
    Mogensen SC. Role of macrophages in natural resistance to virus infections. Microbiol Rev 1979;43:1–26.PubMedGoogle Scholar
  75. 75.
    Fraser-Smith EB, Matthews TR. Protective effect of muramyl dipeptide analogs against infections ofPseudomonas aeruginosa orCandida albicans in mice. Infect Immun 1981;34:676–83.PubMedGoogle Scholar
  76. 76.
    Sone S. Role of alveolar macrophages in pulmonary neoplasis. Biochim Biophys Acta 1986;823:227–45.PubMedGoogle Scholar
  77. 77.
    Smolin G, Okumoto M, Scott F, Condon D. Idoxuridine — liposome therapy for Herpes simplex keratitis. Am J Ophthalmol 1981;91:220–5.PubMedGoogle Scholar
  78. 78.
    Schaeffer HE, Krohn DLK. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 1982;22:220–7.PubMedGoogle Scholar
  79. 79.
    Singh K, Mezei M. Liposomal ophthalmic drug delivery system. II. Dihydrostreptomycin sulfate. Int J Pharm 1984;19:263–9.Google Scholar
  80. 80.
    Arrowsmith M, Hadgraft J, Kellaway IW. Thein vitro release of steroids from liposomes. Int J Pharm 1983;14:191–208.Google Scholar
  81. 81.
    Panzer EA, Jansons VK. Control ofin vitro cytotoxicity of positively charged liposomes. J Cancer Res Clin Oncol 1979;95:2.Google Scholar
  82. 82.
    Crommelin DJA, Storm G. Controlled Drug Delivery. Stuttgart: Verlagsgesellschaft mbH, 1987:80–91.Google Scholar
  83. 83.
    Zonneveld GM, Crommelin DJA. Liposomes as Drug Carriers: Trends and Progress. Chichester: John Wiley & Sons Ltd. (in press).Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1987

Authors and Affiliations

  • F. Emmen
    • 1
  • G. Storm
    • 1
  1. 1.Department of Pharmaceutics, Subfaculty of PharmacyState University of UtrechtAD UtrechtThe Netherlands

Personalised recommendations